Category Archives: Aesthetic Medicine

SEREMBAN: A national registry on doctors and specialists in aesthetic medicine will be set up to curb allegations of disfigurements or deaths arising from aesthetic procedures performed by incompetent medical and non-medical practitioners. Medical and surgical specialists will be required to possess a higher qualification and be properly trained in their respective fields before they can have their names included in the National Registry of Registered Medical Practitioners Practising Aesthetic Medical Practice. These are among new provisions introduced by the Health Ministry in a move to regulate the industry following a significant increase in the number of doctors engaging in this practice. Health director-general Datuk Dr Noor Hisham Abdullah said the main objective of the registry was to ensure the safety of aesthetic medical practice in Malaysia. In recent years, aesthetic medical practice has gained popularity and as it is a consumer-driven service, the public needs to be protected. Aesthetic medical practice is not risk-free as many may perceive. In the pursuit of trying to satisfy the aesthetic desires of patients, practitioners need to be aware of the health risks and potential complications, he said in the foreword of the just-released Guidelines on Aesthetic Medical Practice for Registered Medical Practitioners … Continue reading →

SEREMBAN: A national registry on doctors and specialists in aesthetic medicine will be set up to curb allegations of disfigurements or deaths arising from aesthetic procedures performed by incompetent medical and non-medical practitioners. Medical and surgical specialists will be required to possess a higher qualification and be properly trained in their respective fields before they can have their names included in the National Registry of Registered Medical Practitioners Practising Aesthetic Medical Practice. These are among new provisions introduced by the Health Ministry in a move to regulate the industry following a significant increase in the number of doctors engaging in this practice. Health director-general Datuk Dr Noor Hisham Abdullah said the main objective of the registry was to ensure the safety of aesthetic medical practice in Malaysia. In recent years, aesthetic medical practice has gained popularity and as it is a consumer-driven service, the public needs to be protected. Aesthetic medical practice is not risk-free as many may perceive. In the pursuit of trying to satisfy the aesthetic desires of patients, practitioners need to be aware of the health risks and potential complications, he said in the foreword of the just-released Guidelines on Aesthetic Medical Practice for Registered Medical Practitioners … Continue reading →

IAPAM's Aesthetic Medicine Symposium Botox Training - Testimonial Visit http://iapam.com/aesthetic-medicine-symposium-botox-training to learn more about IAPAM's Aesthetic Medicine Accreditation and Botox Training, or call 1... By: iapam … Continue reading →

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. o Launch expected in April 2013 PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines." About Dysport The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of … Continue reading →

BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada 09.04.2013, 07:30:03 MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. o Launch expected in April 2013 PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for DysportR (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DysportR for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind DysportR and to extend its geographical footprint. After its approval in 2009 in the United States, DysportRwill now be available in Canada for the treatment of glabellar lines." About DysportR The active substance in DysportR is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted … Continue reading →

By RTT News, April 09, 2013, 01:46:00 AM EDT (RTTNews.com) - Ipsen (IPSEY.PK) said that it was granted a marketing authorization for Dysport by Health Canada for the temporary improvement in the appearance of moderate to severe frown lines in adult patients younger than 65 years of age. Medicis Aesthetics Canada, an unit of Valeant Pharmaceuticals, would market Dysport for use in aesthetic medicine in Canada. The launch may take place in April 2013. The company said in a statement: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysport will now be available in Canada for the treatment of glabellar lines." The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. For comments and feedback: contact editorial@rttnews.com http://www.rttnews.com More here: Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada - Quick Facts … Continue reading →

PARIS & MONTREAL--(BUSINESS WIRE)-- Regulatory News: Ipsen (IPN.PA) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsens group, stated: This presentation is in line with Ipsens commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines. About Dysport The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia (or spasmodic torticollis, a chronic condition in which the neck is twisted or deviated), spasticity of the upper/lower … Continue reading →